As filed with the Securities and Exchange Commission on May 6, 2020

Registration No. 333-232487

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1

TO

FORM S-3

REGISTRATION STATEMENT (REG. NO. 333-232487)

UNDER

THE SECURITIES ACT OF 1933

 

 

BIONTECH US INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   46-3915846

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

40 Erie Street, Suite 110

Cambridge, MA 02139

(Address, including zip code, of registrant’s principal executive offices)

 

 

BioNTech USA Holding, LLC

228 E 45th Street, Suite 9e

New York, NY 10017

(Name and address of agent for service)

(347) 694-5321

(Telephone number, including area code, of agent for service)

 

 

Approximate date of commencement of proposed sale to the public: Not applicable

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:  ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:  ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:  ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
Emerging growth company       

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☒

 

 

 


DEREGISTRATION OF SECURITIES

This Post-Effective Amendment (the “Post-Effective Amendment”) relates to the Registration Statement on Form S-3 (File No. 333-232487), filed with the Securities and Exchange Commission (the “SEC”) on July 1, 2019 (the “Registration Statement”) by BioNTech US Inc. (f/k/a Neon Therapeutics, Inc.), a Delaware corporation (the “Registrant”).

On May 6, 2020, pursuant to the terms of an Agreement and Plan of Merger (the “Merger Agreement”) dated as of January 15, 2020 by and among BioNTech SE, a Societas Europaea existing under the laws of Germany and the European Union (“Parent”), Endor Lights, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (the “Merger Sub”) and the Registrant, Merger Sub merged with and into the Registrant, with the Registrant surviving the merger as a direct, wholly owned subsidiary of Parent (the “Merger”).

As a result of the Merger, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statement. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statement that remain unissued at the termination of the offering, the Registrant hereby removes from registration all securities registered but unsold under such Registration Statement, if any, as of the date hereof.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-3 and has duly caused the Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts on May 6, 2020.

 

BioNTech US Inc. (f/k/a Neon Therapeutics, Inc.)
By:   /s/ Richard Gaynor
  Richard Gaynor
  President of Research & Development
Neon Therapeutics (NASDAQ:NTGN)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Neon Therapeutics Charts.
Neon Therapeutics (NASDAQ:NTGN)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Neon Therapeutics Charts.